Sensei Biotherapeutics, Inc.
SNSEDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Jun 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How SNSE's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SNS-101 (anti-VISTA) | Phase 2 | Solid Tumor, Adult | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Sensei Biotherapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Sensei Biotherapeutics, Inc.'s (SNSE) pipeline across Phase 2. Its lead program is SNS-101 (anti-VISTA) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Sensei Biotherapeutics, Inc.'s next FDA catalyst?→
Sensei Biotherapeutics, Inc.'s (SNSE) next tracked catalyst is a Phase 2 expected June 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SNSE biotech catalysts?→
Add SNSE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Sensei Biotherapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.